Table 3.
Characteristics of microarray datasets for platform, sample groups, and grade, type and stage in endometrial cancers
| Characteristics | Training dataset (n = 273) | Validation set A (n = 40) | Validation set B (n = 90) |
|---|---|---|---|
|
Sample |
|
|
|
| Control |
37 (14%) |
20 (50%) |
45 (50%) |
| Case |
236 (86%) |
20 (50%) |
45 (50%) |
|
Grade
a
|
|
|
|
| G1 |
86 (36%) |
|
20 (44%) |
| G2 |
43 (18%) |
- |
12 (27%) |
| G3 |
52 (22%) |
- |
8 (18%) |
| Unknown |
55 (23%) |
- |
5 (11%) |
|
Type
a
|
|
|
|
| T1 |
113 (48%) |
10 (50%) |
- |
| T2 |
84 (36%) |
10 (50%) |
- |
| Unknown |
39 (17%) |
0 |
- |
|
Stage
a
|
|
|
|
| IA |
31 (13%) |
10 (50%) |
10 (22%) |
| IB |
37 (16%) |
- |
10 (22%) |
| IC or late stage |
23 (10%) |
10 (50%) |
19 (42%) |
| Unknown |
82 (61%) |
0 |
6 (14%) |
|
Platform |
|
|
|
| Affymetrix |
140 |
- |
- |
| Illumina |
19 |
20 |
- |
| Agilent |
114 |
- |
- |
| Swegene | - | - | 45 |
aEndometrial cancers are grouped by the grade (degree of differentiation), type (histopathological types) and stage (status of spread).